Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  HspE7
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-7 of 7 for your search:
Start Over
SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
Phase: Phase II, Phase I
Type: Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02507, AMC-035, CDR0000258786, NCT00052897
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 17 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02513, GOG-0197, U10CA027469, CDR0000269709, NCT00054041
SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia
Phase: Phase II
Type: Prevention
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000347077, AECM-0309225, NCI-5850, 5850, NCT00075569
A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis
Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: 2 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: Stressgen SGN-00101-0005, SGN-00101-0005, NCT00038714
SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 18 to 50
Sponsor: NCI
Protocol IDs: NCI-2012-02623, UCI#02-55, N01CN25139, CDR0000383786, UCIRVINE-02-55, UCIRVINE-2002-2758, NCT00091130
Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia
Phase: Phase I
Type: Prevention
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HspE7-00101-0601, NCT00493545
Start Over